ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / QTEX / financials
SKIN (32) LNSR (18) MBOT (29) DXR (47) ⌘ Pro Terminal β†’

QTREX Quantum Ltd. (QTEX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.12 -8.20% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.10

QTREX Quantum Ltd. (QTEX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $62.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QTEX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is QTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.12 (-8.20% 1D, market cap $62.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QTEX ranks #570 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does QTEX compare to SKIN and LNSR in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, SKIN (SkinHealth Systems Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -26.9%, cap $67.5M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $69.7M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QTEX?
β–Ό

Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue (-99.1% YoY), -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.10 (-1.67%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (7)Whales (10)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$4 Bull$1 Base$1 Bear
πŸ“¬ FREE QTEX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for QTEX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
πŸ” WHY QTEX SCORES 36/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+10/20 pts (28% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
44
Grade D$1.58-7.6% Next Q
Q2 (-2Q)
41
Grade D$1.46-7.5% Next Q
Q3 (-1Q)
39
Grade E$1.35-17% Next Q
Current
36
Grade D-$1.12-8.3% Hist 90D Ξ±
Trajectory: D (44) β†’ D- (36)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a QTEX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While QTEX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.10) and Max Pain ($1.18) forces dealer call-delta covering toward $4.04.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QTEXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œQTEX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How QTEX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.0MGross Profit $2.0K (0.2%)Cost of Sales $998.0KOp Profit $0 (0%)OpEx (R&D/SG&A) $2.0KNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $34.0M
FY24
Rev $31.5M
FY25
Rev $289.0K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$289.0K0.7%-80%-$13.2M-$10.0M-45%
FY 2024$31.5M8%-35.7%-$11.1M-$9.5M-45%
FY 2023$34.0M8%-35.7%-$11.3M-$9.7M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTEX)

  • βœ“Walkthrough of QTEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
QTEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +133.33%πŸ“ HORIZONTAL RANGE
2026-11-04O $1.22H $1.22L $1.12C $1.12VOL 2.73M
RES: $2.20SUP: $0.43SMA50: $1.10SMA200: $0.97
$4.10$3.06$2.03$0.99$-0.04RES $2.20SUP $0.43$1.122026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QTEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ QTEX Butterfly Map β†’ + Track QTEX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QTEX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for QTEX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QTEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTEX)

Health Care Rank #570 of 1015 βš”οΈ SKIN vs QTEX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (QTEX vs. SKIN, LNSR, MBOT, DXR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, QTREX Quantum Ltd. (QTEX) ranks #570 by composite RQD confidence (36/100, grade D-) and #711 by equity capitalization ($62.7M). Within this direct 5-issuer industry benchmark cohort, QTEX leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and β€” gross margin. DXR currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QTEX at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QTEX ACTIVE
QTREX Quantum Ltd.
D- 36/100 β€” 0.7% -35.0% -8.20% $62.7M Benchmark Subject
SKIN
SkinHealth Systems Inc. (Class A)
E 32/100 β€” 65.3% -26.9% +4.43% $67.5M /skin-vs-qtex β†’
LNSR
LENSAR Inc.
E 18/100 β€” 39.4% -35.0% -2.91% $69.7M /lnsr-vs-qtex β†’
MBOT
Microbot Medical Inc.
E 29/100 β€” β€” -15.8% -4.59% $69.9M /mbot-vs-qtex β†’
DXR
Daxor Corporation
D 47/100 β€” β€” β€” -2.17% $52.5M /dxr-vs-qtex β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001837493 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), QTREX Quantum Ltd. (QTEX) reported GAAP revenue of $289.0K (-99.1% vs. FY2024 revenue of $31.5M , and -99.1% cumulative change since FY2023) , GAAP net income of -$13.2M, operating cash flow of -$9.9M, and free cash flow of -$10.0M (-4.5% YoY). On the balance sheet, QTEX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $289.0K -$13.2M -$9.9M -$10.0M $5.3M β€”
FY2024 (FY) 2024-12-31 $31.5M -$11.1M -$9.4M -$9.5M $8.1M β€”
FY2023 (FY) 2023-12-31 $34.0M -$11.3M -$9.7M -$9.7M β€” β€”

3. QTEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.12 (-8.20% 1D, market cap $62.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QTEX ranks #570 in composite RQD confidence.

How does QTEX compare to SKIN and LNSR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, SKIN (SkinHealth Systems Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -26.9%, cap $67.5M) and LNSR (LENSAR Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $69.7M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QTEX?

Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue (-99.1% YoY), -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QTEX trading relative to its 50-day, 200-day, and 52-week technical levels?

QTEX last traded at $1.12 (-8.20% on volume of 2,729,255 shares), positioning the stock +1.82% above its 50-day simple moving average ($1.10) and +15.46% above its 200-day simple moving average ($0.97). Across its 52-week range of $0.28 to $3.85, QTEX sits at the 23.5% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.26).

Direct Sub-Reports: QTEX RQD Cockpit QTEX 12M Forecast QTEX Earnings & Move QTEX Dividends & DRIP QTEX Insiders & 13F QTEX Whale Options QTEX Profit Sankey QTEX News & Why
ROARABLE RATING BRIEF β€’ RQD 36/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

QTEX β€” QTREX Quantum Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

QTREX Quantum Ltd. (QTEX) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.12 (-8.20% 1D, market capitalization $62.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 0.7%, operating margin of -60.0%, and free cash flow yield of -13.49%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

QTREX Quantum Ltd. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile does not describe its products, customers, or revenue model. Reported revenue is $0.3M for FY 2025 and β€” for both FY 2024 and FY 2023, indicating minimal commercial revenue against operating losses.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), QTREX Quantum Ltd. (QTEX) reported $289.0K in annual revenue (up from $31.5M in FY2024, -99.1% YoY) and -$13.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.0M revenue, -$11.3M net income) through FY2025, QTEX scaled operating cash flow to -$9.9M and free cash flow to -$10.0M, backed by $5.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.49% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.28 – $3.85 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care / Medical/Dental Instruments classification. A prospective investor should watch whether the quantum test results referenced in the news flow translate into any commercial revenue, since current revenue of $0.3M provides little operating base to absorb further losses.

  • Key Question #1: Can QTEX sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $289.0K and free cash flow of -$10.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is QTEX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QTEX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for QTREX Quantum Ltd. (QTEX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to QTEX Debate Forum (3) ↓
🟒 CATALYST Globes - Israel Business News β€’ 2d ago
Qtrex Quantum jumps 40%

Globes - Israel Business News report covering QTREX Quantum Ltd. (QTEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QTEX Bull vs. Bear Conversation Board β€” What's Your Call at $1.12?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QTEX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QTEX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $1.54 (+26.2%)
πŸ“Œ Pinned Debate

Shares surged after hours on quantum test results and the company regained Nasdaq bid-price compliance, preserving capital-market acces

Long QTEX at $1.22 targeting $1.54. Shares surged after hours on quantum test results and the company regained Nasdaq bid-price compliance, preserving capital-market access.. Institutional whale score is 10/20 and the risk/reward vs. the $0.28 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd πŸ‚ BULL

@TapeReader_Pro Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.22 and keeping dry powder in case we test $1.13.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.93 (-23.8%)
Spot @ $1.22

Negative FCF of -$10.0M against $0.3M revenue, a Piotroski F-Score of 2/9, and ROIC of -35% signal sustained cash burn and weak forensi

Fading this rally in QTEX at $1.22. Negative FCF of -$10.0M against $0.3M revenue, a Piotroski F-Score of 2/9, and ROIC of -35% signal sustained cash burn and weak forensic health.. With a beta of 1.0 and the stock sitting at $1.22 (52-wk range $0.28–$3.85), the easy multiple expansion is already priced in.

LIVE TAPE